MAPT and Alzheimer disease: Our results confirm a clear impact of ApoE4 on all CSF AD core biomarkers: (1) In our total sample, ApoE4 carriers had lower concentration of CSF Aβ42, and increased concentration of t-tau and p-tau than non-carriers in a gene-dose-dependent manner.